A recent Nature article reports a preclinical GLP-1GIPlanifibranor conjugate: a unimolecular quintuple agonist designed to combine GLP-1R/GIPR co-agonism with PPAR// agonism
GHRH(1-29) analog for physiological growth hormone stimulation research CJC-1295 (No-DAC) + Ipamorelin: the synergy stack CJC-1295 is GHRH(1-29) with four stabilizing amino acid substitutions (among them D-Ala at position 2, which blocks DPP-IV degradation) [PMID 7962295]
*Correspondence: Na Ren, [email protected] Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
What clinical evidence supports GLP-1 medications for weight loss
Patients have reported decreased interest in alcohol and nicotine when taking GLP-1s, and observational studies have shown an association between treatment with GLP-1 medication and lower risk of alcohol and cannabis use disorders, opioid overdose, and alcohol-related hospitalization
Oral semaglutide (Rybelsus) has dramatically different pharmacokinetics, with bioavailability around 1%
